Trial Profile
A Double-blind, Placebo-controlled, Randomised Study of the Efficacy of an HPV-16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Healthy Adolescent and Young Adult Women in North America and Brazil.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Jan 2008 Status changed from in progress to completed.
- 30 Sep 2006 New trial record.